AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).

Employees

55,000

Sector

Pharmaceuticals

Calendar

07-24 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
13/06/25	191.08 $	-0.70%	4,965,775
12/06/25	192.42 $	+0.48%	5,781,429
11/06/25	191.50 $	+1.06%	3,907,958
10/06/25	189.50 $	+0.18%	4,087,503
09/06/25	189.16 $	-0.35%	4,661,638

Delayed Quote Nyse, June 13, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

191.08USD

Average target price

208.86USD

Spread / Average Target

+9.31%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:02 13/06/2025 BST			5-day change	1st Jan Change
191.08 ^USD	-0.70%		+0.66%	+7.53%

06-12	Daewoong Pharmaceutical Launches Nabota in Qatar, Expands Presence in High-Potential Gcc Aesthetic Market	CI
06-12	Amneal Pharmaceuticals Wins US FDA Approval for Generic Pred Forte; Launch Planned for Q3	MT

Capitalization	338B 292B 274B 248B 458B 29,060B 518B 3,202B 1,246B 13,304B 1,267B 1,240B 48,599B	P/E ratio 2025 *	28.6x	P/E ratio 2026 *	21.5x
Enterprise value	392B 339B 318B 288B 532B 33,751B 602B 3,719B 1,447B 15,451B 1,471B 1,440B 56,443B	EV / Sales 2025 *	6.55x	EV / Sales 2026 *	5.92x
Free-Float	96.39%	Yield 2025 *	3.42%	Yield 2026 *	3.59%

Daewoong Pharmaceutical Launches Nabota in Qatar, Expands Presence in High-Potential Gcc Aesthetic Market	06-12	CI
Amneal Pharmaceuticals Wins US FDA Approval for Generic Pred Forte; Launch Planned for Q3	06-12	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	06-11	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	06-11	MT
Sector Update: Health Care	06-11	MT
AbbVie Receives FDA Label Expansion Approval for Mavyret to Treat Hepatitis C	06-11	MT
U.S. FDA Approves Expanded Indication for Abbvie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus	06-11	CI
AbbVie Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11:20 AM	06-11
Drug pricing reform talks with US government lack clarity, industry executives say	06-10	RE
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial	06-10	RE
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO	06-09	RE
Analyst recommendations: AbbVie, Emerson Electric, Marriott International, Zscaler, and Monster Beverage…	05-30
Berenberg Adjusts Price Target on AbbVie to $170 From $195, Maintains Hold Rating	05-30	MT

Analyst recommendations: AbbVie, Emerson Electric, Marriott International, Zscaler, and Monster Beverage…	05-30
Berenberg Adjusts Price Target on AbbVie to $170 From $195, Maintains Hold Rating	05-30	MT
Ameriprise Financial Initiates AbbVie at Buy	05-20	MT
Analyst recommendations: AbbVie, KKR, Merck, Toast, Uber…	05-14
Citigroup Downgrades AbbVie to Neutral From Buy, Adjusts Price Target to $205 From $210	05-14	MT

AbbVie Inc. Share Price

Equities

ABBV

US00287Y1091

Pharmaceuticals

Valuation: AbbVie Inc.

Chart: AbbVie Inc.

Latest news: AbbVie Inc.

Last Transcript: AbbVie Inc.

Analysts' recommendations: AbbVie Inc.

Press Releases: AbbVie Inc.

News in other languages: AbbVie Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbbVie Inc.

ETFs: AbbVie Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET as First and Only Treatment for People with Acute Hepatitis C Virus	06-12	AQ
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals	06-04	AQ
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals	06-03	PR
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference	06-03	PR
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV	05-30	PR

Boeing, Micron, Oracle... Les valeurs à suivre aujourd'hui à Wall Street -	06-12
Abbvie : annonce l'extension de la notice d'utilisation du Mavyret	06-12
Trump et Xi ont des choses à se dire	06-03
Bourse Europe : serial-acquisitions en France, fusion foncière belge XXL et chute de Temu	06-03
Roche erhält US-Zulassung für Ventana Met-Diagnostiktool im Bereich Lungenkrebs	05-14

1 day	-0.70%
1 week	+0.66%
Current month	+2.67%
1 month	+1.64%
3 months	-9.68%
6 months	+10.22%
Current year	+7.53%

1 week	187.41	193.59
1 month	176.57	193.59
Current year	164.39	218.66
1 year	163.52	218.66
3 years	130.96	218.66
5 years	79.11	218.66
10 years	45.45	218.66

Manager	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	54	30/06/2024
Scott Reents DFI	Director of Finance/CFO	58	22/06/2022
Roopal Thakkar CTO	Chief Tech/Sci/R&D Officer	-	31/12/2002

Director	Title	Age	Since
Richard Gonzalez CHM	Chairman	71	31/12/2012
Roxanne Austin BRD	Director/Board Member	64	31/12/2012
William Burnside BRD	Director/Board Member	73	31/12/2012

Name	Weight	AuM	1st Jan change
FIRST TRUST MORNINGSTAR DIVIDEND LEADERS ETF (CAD-HEDGED) - CAD	7.12%	6 M€	0.00%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	6.85%	21 M€	+0.03%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ABBVIE INC.	-0.70%	+0.66%	+14.72%	+37.05%	340B
ELI LILLY AND COMPANY	+0.90%	+6.43%	-7.24%	+181.30%	729B
JOHNSON & JOHNSON	+0.28%	+1.34%	+8.01%	-8.03%	377B
NOVO NORDISK A/S	-0.58%	+5.27%	-47.31%	+34.04%	358B
ROCHE HOLDING AG	-1.06%	+0.56%	+9.72%	-12.79%	269B
NOVARTIS AG	-0.93%	+0.08%	+3.08%	+17.37%	236B
ASTRAZENECA PLC	-0.40%	+1.89%	-11.35%	+12.37%	232B
MERCK & CO., INC.	-0.13%	+3.47%	-36.84%	-3.87%	205B
AMGEN INC.	-0.70%	+1.68%	-1.10%	+24.69%	160B
PFIZER, INC.	-1.21%	+5.10%	-11.25%	-48.78%	141B
Average	-0.56%	+3.53%	-7.96%	+23.34%	304.74B
Weighted average by Cap.	-0.53%	+4.01%	-7.48%	+50.44%

	2025 *	2026 *
Net sales	59.87B 51.79B 48.6B 44.04B 81.31B 5,155B 91.96B 568B 221B 2,360B 225B 220B 8,620B	64.64B 55.92B 52.47B 47.55B 87.79B 5,566B 99.3B 613B 239B 2,548B 243B 237B 9,308B
Net income	11.66B 10.09B 9.46B 8.58B 15.83B 1,004B 17.91B 111B 43.04B 460B 43.76B 42.81B 1,679B	15.36B 13.29B 12.47B 11.3B 20.87B 1,323B 23.6B 146B 56.72B 606B 57.67B 56.43B 2,212B
Net Debt	54.48B 47.13B 44.22B 40.08B 73.99B 4,691B 83.69B 517B 201B 2,147B 204B 200B 7,845B	45.15B 39.06B 36.65B 33.21B 61.32B 3,887B 69.36B 428B 167B 1,780B 169B 166B 6,501B